Bright Minds initiated with a Buy at Chardan

Chardan analyst Rudy Li initiated coverage of Bright Minds (DRUG) with a Buy rating and $80 price target The firm cites the potential of the company’s lead asset BMB-101 for the treatment of epilepsy for the Buy rating. Bright Minds is an “interesting story even at current valuation: as BMB-101 could be differentiated verses other 5-HT2C agonists with its unique binding profile, and it could potentially achieve greater than $1B peak sales in epilepsy, the analyst tells investors in a research note.